Dr. Inge van Oort completed her urological training at het Radboud University Nijmegen Medical Centre, the Netherlands, in 2006. In that same year she started her fellowship in oncological urology and she also became part of the faculty at the Radboud University Nijmegen Medical Centre (chairman: Peter Mulders). In 2008 she was appointed as an oncological urologist and senior staff member.
In 2009, she obtained her PhD on the clinical relevance of pathological findings after radical prostatectomy at the department of Urology at the Radboud University Nijmegen Medical Centre.
Her main interest in oncological urology is the (surgical) treatment of prostate and bladder cancer. In research she has interests in finding new moleculair markers in prostate cancer and in the treatment of castration resistant prostate cancer. She also has been part of several large trials in CRPC (i.e Cougar 301 and 302 (abiraterone), Proselica and compassionate use program (cabazitaxel), Affirm and Previal (enzalutamide), provenge (sipuleucel-T), orteronel).
On national level she has been part of several activities at the Dutch Urological Society (DUA). She is the chair of the working group on Oncological Urology (WOU), member of the board of education for residents (CCO), and member of the “Quality of care” group. In 2013 she was member of the multidisciplinairy Dutch guideline group on prostate cancer.
At the EAU she’s a member of the EAU Guideline Office- new media group and was part of the Young acacdemic Urologists (prostare cancer group) from 2011-2014.
In 2013 she received a grant from the Dutch cancer foundation for a study on Quality of care in prostate cancer treatment.
Inge M. van Oort is member of national and international urological and oncological associations. She is also reviewer for national and international journals and member of the editorial board of the world journal of Urology.